Researchers from Szczecin, Poland, assessed the efficacy of Lactobacillus plantarum 299V (LP299V) in patients with irritable bowel syndrome (IBS).
The therapeutic options for IBS are limited. Recent reports suggest that probiotics may have a role in regulating the motility of the digestive tract.
A total of 40 patients were randomized to receive either LP299V in liquid suspension (20 patients) or placebo (20 patients), over a period of 4 weeks.
Clinical examination was performed at baseline and at the end of the study.
|Improvement in all IBS symptoms:|
| European Journal of Gastroenterology & Hepatology |
Additionally, patients assessed their symptoms by applying a scoring system.
The team found that all patients treated with LP299V reported resolution of their abdominal pain, as compared to 11 patients from the placebo group.
There was also a trend towards normalization of stools frequency in constipated patients, in 6 out of 10 patients treated with LP299V, compared with 2 out of 11 treated with placebo.
With regards to all IBS symptoms, an improvement was noted in 95% of patients in the LP299V group, compared to 15% of patients in the placebo group.
Krzysztof Niedzielin, of the Marie Curie Regional Hospital, concluded on behalf of fellow colleagues, "LP299V seems to have a beneficial effect in patients with IBS.
"Further studies on larger cohorts of patients, and with longer duration of therapy, are required in order to establish the place of L. plantarum in the treatment of IBS."